Literature DB >> 35809219

Cognitive frailty and 5-year adverse health-related outcomes for the Malaysian elders longitudinal research (MELoR) study.

Janice Ying Qian Ong1, Sumaiyah Mat1,2, Sheng Hui Kioh1,3, Kejal Hasmuk1,4, Nor'izzati Saedon1,4, Hazlina Mahadzir5, Ai-Vyrn Chin1,4, Shahrul Bahyah Kamaruzzaman1,4, Maw Pin Tan6,7,8.   

Abstract

PURPOSE: To determine the risk of adverse outcomes among prefrail and frail individuals with and without cognitive impairment as well as those with isolated cognitive impairment compared to robust individuals without cognitive impairment.
METHODS: Data from the Malaysian elders longitudinal research (MELoR) study were utilised. Baseline data were obtained from home-based computer-assisted interviews and hospital-based health-checks from 2013 to 2015. Protocol of MELoR study has been described in previous study (Lim in PLoS One 12(3):e0173466, 2017). Follow-up interviews were conducted in 2019 during which data on the adverse outcomes of falls, sarcopenia, hospitalization, and memory worsening were obtained. Sarcopenia at follow-up was determined using the strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F) questionnaire.
RESULTS: Follow-up data was available for 776 participants, mean (SD) age 68.1 (7.1) years and 57.1% women. At baseline, 37.1% were robust, 12.8% had isolated cognitive impairment, 24.1% were prefrail, 1.0% were frail, 20.2% were prefrail with cognitive impairment, and 4.8% had CF. Differences in age, ethnicity, quality of life, psychological status, function and comorbidities were observed across groups. The association between CF with hospitalisation and falls compared to robust individuals was attenuated by ethnic differences. Pre-frail individuals were at increased risk of memory worsening compared robust individuals [aOR(95%CI) = 1.69 (1.09-2.60)]. Frail [7.70 (1.55-38.20)], prefrail with cognitive impairment [3.35 (1.76-6.39)] and CF [6.15 (2.35-16.11)] were significantly more likely to be sarcopenic at 5-year follow-up compared to the robust group.
CONCLUSIONS: Cognitive frailty was an independently predictor of sarcopenia at 5-year follow-up. The relationship between CF with falls and hospitalization, however, appeared to be accounted for by ethnic disparities. Future studies should seek to unravel the potential genetic and lifestyle variations between ethnic groups to identify potential interventions to reduce the adverse outcomes associated with CF.
© 2022. The Author(s), under exclusive licence to European Geriatric Medicine Society.

Entities:  

Keywords:  Accidental falls; Aged; Cognitive impairment; Frailty; Hospitalization; Sarcopenia

Year:  2022        PMID: 35809219     DOI: 10.1007/s41999-022-00673-x

Source DB:  PubMed          Journal:  Eur Geriatr Med        ISSN: 1878-7649            Impact factor:   1.710


  25 in total

1.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

2.  Frailty and incident dementia.

Authors:  Shelly L Gray; Melissa L Anderson; Rebecca A Hubbard; Andrea LaCroix; Paul K Crane; Wayne McCormick; James D Bowen; Susan M McCurry; Eric B Larson
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-02-18       Impact factor: 6.053

3.  Consequences of physical inactivity in older adults: A systematic review of reviews and meta-analyses.

Authors:  Conor Cunningham; Roger O' Sullivan; Paolo Caserotti; Mark A Tully
Journal:  Scand J Med Sci Sports       Date:  2020-02-04       Impact factor: 4.221

4.  Cognitive frailty: rational and definition from an (I.A.N.A./I.A.G.G.) international consensus group.

Authors:  E Kelaiditi; M Cesari; M Canevelli; G Abellan van Kan; P-J Ousset; S Gillette-Guyonnet; P Ritz; F Duveau; M E Soto; V Provencher; F Nourhashemi; A Salvà; P Robert; S Andrieu; Y Rolland; J Touchon; J L Fitten; B Vellas
Journal:  J Nutr Health Aging       Date:  2013-09       Impact factor: 4.075

5.  Cognitive Frailty and Adverse Health Outcomes: Findings From the Singapore Longitudinal Ageing Studies (SLAS).

Authors:  Liang Feng; Ma Shwe Zin Nyunt; Qi Gao; Lei Feng; Keng Bee Yap; Tze-Pin Ng
Journal:  J Am Med Dir Assoc       Date:  2016-11-09       Impact factor: 4.669

6.  Frailty syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Aging.

Authors:  Vincenzo Solfrizzi; Emanuele Scafato; Vincenza Frisardi; Davide Seripa; Giancarlo Logroscino; Stefania Maggi; Bruno P Imbimbo; Lucia Galluzzo; Marzia Baldereschi; Claudia Gandin; Antonio Di Carlo; Domenico Inzitari; Gaetano Crepaldi; Alberto Pilotto; Francesco Panza
Journal:  Alzheimers Dement       Date:  2012-12-12       Impact factor: 21.566

7.  Burden of frailty in the elderly population: perspectives for a public health challenge.

Authors:  Fanny Buckinx; Yves Rolland; Jean-Yves Reginster; Céline Ricour; Jean Petermans; Olivier Bruyère
Journal:  Arch Public Health       Date:  2015-04-10

8.  Frailty is an independent predictor of incident dementia: Evidence from the English Longitudinal Study of Ageing.

Authors:  Nina T Rogers; Andrew Steptoe; Dorina Cadar
Journal:  Sci Rep       Date:  2017-11-16       Impact factor: 4.379

9.  Prevalence, risk factors and health outcomes associated with polypharmacy among urban community-dwelling older adults in multi-ethnic Malaysia.

Authors:  Li Min Lim; Megan McStea; Wen Wei Chung; Nuruljannah Nor Azmi; Siti Azdiah Abdul Aziz; Syireen Alwi; Adeeba Kamarulzaman; Shahrul Bahyah Kamaruzzaman; Siew Siang Chua; Reena Rajasuriar
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

10.  Cognitive and Physical Function in Relation to the Risk of Injurious Falls in Older Adults: A Population-Based Study.

Authors:  Anna-Karin Welmer; Debora Rizzuto; Erika J Laukka; Kristina Johnell; Laura Fratiglioni
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-05-01       Impact factor: 6.053

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.